Necrostatin-1

Catalog No.S8037

Necrostatin-1 Chemical Structure

Molecular Weight(MW): 259.33

Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells.

Size Price Stock Quantity  
USD 97 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 34 Publications

Purity & Quality Control

Choose Selective TNF-alpha Inhibitors

Biological Activity

Description Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells.
Features A powerful tool for characterizing the role of necroptosis with characterized primary target.
Targets
RIP1 [1]
(293T cells)
490 nM(EC50)
In vitro

Necrostatin-1 (1-100 μM) inhibits the autophosphorylation of overexpressed and endogenous RIP1.It is found RIP1 is the primary cellular target responsible for the antinecroptosis activity of Necrostatin-1. [1] Necrostatin-1 efficiently suppresses necroptotic cell death triggered by an array of stimuli in a variety of cell types. Necrostatin-1, previously identified as small-molecule inhibitor of necroptosis, inhibits RIP kinase-induced necroptosis and inhibits TNF-α-induced necroptosis in jurkat cells with EC50 of 490 nM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NYK1Z2F7S2WubDDWbYFjcWyrdImgRZN{[Xl? MnXmOVDDqM7:TR?= NGm0fZczPMLiaB?= NFzQXlNqdmirYnn0d{BOVVNvaX7keYNm\CClZXzsJIRm[XSq Mk\4NlY1PzJ5MkO=
MEFs  NIjidI1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mle3NVDjiIoQvF2= NIGyVFg1QCCq MVPEUXNQ MWTpcohq[mm2czD6WmFFNXC{b33veIVlKGSnYYToJI9nKEOQT2SzMYRmeGyndHXkJG1GTnN? Mk\ONlY1Ozd5OEm=
BMDM  NGPTSYpHfW6ldHnvckBCe3OjeR?= MXyxNOKh|ryP MoDRN|DDqG2rbh?= NF7IdXNxem:2ZXP0d{Bk\WyuczDmdo9uKFSDS1mtbY5lfWOnZDDMSGghemWuZXHz[S=> NXfDRmk{OjZ|OEG2NFE>
NCI-H28 M4m3emNmdGxiVnnhZoltcXS7IFHzd4F6 MXixNOKh|ryP MlzpNlTDqGh? NF\uWmFxemW4ZX70d{BFSVCHLXnu[JVk\WRicnXkeYN1cW:wIH;mJG5EUS2KMkigZ4VtdCC4aXHibYxqfHoEoB?= NYjRc3lDOjZyMESxN|g>
MiaPaCa-2 Mlz2SpVv[3Srb36gRZN{[Xl? NFrrR4ozOCEQvF2= MXOyOEBp NEK2e5Vl\WO{ZXHz[ZMhfGinIHXhdox6KG6nY4LveIlkKGOnbHzz M2m0ZVI3ODByNkC3
BxPC-3 MlzKSpVv[3Srb36gRZN{[Xl? M1HINlIxKM7:TR?= NYWySVFQOjRiaB?= M3qxeYRm[3KnYYPld{B1cGViZXHycJkhdmWlcn;0bYMh[2WubIO= M3LWbVI3ODByNkC3
SGC-7901 MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NH7QSlc{OMLizszN NEW2TmcyyqCq Mmnhd5VxeHKnc4Pld{BwgGGuaYDsZZRqdi2vZXTpZZRm\CClZXzsJIRm[XSq NXnYd2hUOjV5NkewO|Y>
KMS-12-PE  M37yd2NmdGxiVnnhZoltcXS7IFHzd4F6 MYC2NEDPxE1? MVW1JIg> NVXkbnZ[cW6qaXLpeJMhW0iNLXnu[JVk\WRiY3XscEBl\WG2aB?= Mn6zNlU2OzByOUi=
L929-A  NEjRSVRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NH74PHY2OMLizszNxsA> MoGyNlQhcA>? MXricI9kc3NiVF7G{tEucW6mdXPl[EBk\WyuIHTlZZRp NEDQeJczPTN7OEW0NC=>
L929-N  M3fPcWNmdGxiVnnhZoltcXS7IFHzd4F6 MV61NOKh|ryPwrC= NH3JRXozPCCq NGr5[HdjdG:la4OgWG5H|rFvaX7keYNm\CClZXzsJIRm[XSq NUK3cVJ[OjV|OUi1OFA>
L929-A  M4LqTmZ2dmO2aX;uJGF{e2G7 MX21NOKh|ryPwrC= NInHXYoyOiCq NHi5d3VjdG:la4OgeIhmKGOuZXH2ZYdmKG:oIFPhd5Bie2VvMzDhcoQhWEGUUB?= MnLqNlU{QTh3NEC=
L929-N  NXWzfG5PTnWwY4Tpc44hSXO|YYm= MVy1NOKh|ryPwrC= MmW1NVIhcA>? NFLXZlJjdG:la4OgeIhmKGOuZXH2ZYdmKG:oIFPhd5Bie2VvMzDhcoQhWEGUUB?= NU[zS5AyOjV|OUi1OFA>
L929 MV3GeY5kfGmxbjDBd5NigQ>? NX7CdY56PTEEoN88UeKh NX[5VVRIOTJiaB?= Ml\wbY5pcWKrdIOgWG5H|rFvaX7keYNm\CCEaXSgZ4xm[X[jZ3W= MVeyOVM6QDV2MB?=
L929-A NWDCT|NnTnWwY4Tpc44hSXO|YYm= MV[1NOKh|ryPwrC= MojaNVIhcA>? M2DL[YlvcGmkaYTzJJRp\SCWTldOtU1qdmS3Y3XkJIxwe3Nib3[gcYl1d2Oqb37kdolidCCvZX3idoFv\SCyZYLt[YFjcWyrdIm= MknONlU{QTh3NEC=
L929 NV3XVWJpS2WubDDWbYFjcWyrdImgRZN{[Xl? NFLYdVY{OMLizszN NFTOZ4gyyqCq NWPFfmZVcW6qaXLpeJMhXE6ILd8xMYlv\HWlZXSgcI9{eyCxZjDj[YxtKH[rYXLpcIl1gQ>? M2\NO|I2ODl3N{Sy
L929 MnP6R4VtdCCYaXHibYxqfHliQYPzZZk> M4rwRVMxyqEQvF2= MX:xxsBp MVTpcohq[mm2czDUUmYu|rFvaX7keYNm\CClbHXheoFo\SCxZjDUc5BwKEl? MlLQNlUxQTV5NEK=
Huh7 MmjMR4VtdCCYaXHibYxqfHliQYPzZZk> MWS1NEDDvU1? M1vWeFI1NzR6IHi= MoO2SG1UVw>? MUjwdoV3\W62czDj[YxtKGSnYYToJI9nKHKDZFjDWkBkdy2rbn\lZ5Rm\CCKdXi3JINmdGy| MlrFNlQ6PzN{NEC=
OHC MW\GeY5kfGmxbjDBd5NigQ>? NXvzNFIyOzBy4pEJ{txO M1y2WGROW09? MUnpcoNz\WG|ZYOgco9qe2VvaX7keYNm\CClb37k[Y5{\WRiboXjcIVq MXeyOFg4PDd|NB?=
OHC MUTGeY5kfGmxbjDBd5NigQ>? NGHXXYs{ODEkgJpOwG0> NIflSWRFVVOR MY\k[YNz\WG|ZYOgco9qe2VvaX7keYNm\CC|d3;scIVvKG63Y3zlbeKh MmLYNlQ5PzR5M{S=
OHC M3XzRWZ2dmO2aX;uJGF{e2G7 M1;QTlMxOOLCid88US=> M2D3SWROW09? NEL1XGdz\XO3bITzJIlvKGFicnXkeYN1cW:wIH;mJI5wcXOnLXnu[JVk\WRiUlnQNUBidmRiUlnQN{BqdW23bn;mcJVwemW|Y3XuZ4U> MUWyOFg4PDd|NB?=
OHC MY\GeY5kfGmxbjDBd5NigQ>? MnewN|Ax6oDLzszN M2D0VWROW09? MXPkbY1qdmm|aHXzJI5wcXOnLXnu[JVk\WRiQV3QT{Bi[3SrdnH0bY9v NFXrSXozPDh5NEezOC=>
OHC Ml;wSpVv[3Srb36gRZN{[Xl? MlXpN|Ax6oDLzszN NVTOPIN{TE2VTx?= MWTpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCjcH;weI91cWNiT1jDd{B4cXSqb4X0JIFtfGW{aX7nJJRp\SCuZY\lcJMhd2ZiQ1O4JIFnfGW{IH7vbZNmKGW6cH;zeZJm MUSyOFg4PDd|NB?=
SK-Hep1 MWHGeY5kfGmxbjDBd5NigQ>? MYe2NQKBkc7:TdMg MVmxPQKBkWh? MWTicI9kc3QEoN8yMYxieGGlaH;u[U1qdmS3Y3XkJI1wenCqb3zv[4lk[WxiY3jhcodmNCClZXzsJIRm[XSqIHHu[EBRUSC3cIThb4U> NIPuSGMzPDh|Mk[wNi=>
SK-Hep1 NFSw[4dHfW6ldHnvckBCe3OjeR?= NX\iTHp1PjEkgJpOwG3DqA>? M3jwZlE56oDLaB?= MVHpcohq[mm2czFOtk1N[XCjY3jvcoUucW6mdXPl[EBt\WGtYXflJI9nKEiPR1KtNeKh NYXHVnI{OjR6M{K2NFI>
SK-Hep1 M{K5PWZ2dmO2aX;uJGF{e2G7 M4D6OVYx6oDLzszNxsA> MoriNVjjiImq NH7TdYdjdG:la4RCpO6zNWyjcHHjbI9v\S2vZXTpZZRm\CCSQWKgZYNkfW23bHH0bY9vKGGwZDDBTWYhfHKjboPsc4NifGmxbjD0c{B1cGViY4n0c5NwdMLi MnjFNlQ5OzJ4MEK=
L-540  M1HRXWZ2dmO2aX;uJGF{e2G7 Mn2yOlDjiIoQvH2= M4XROVHjiImq NYjiRVl3eHKndnXueJMhfGinIHflcoVz[XSrb36gc4YhWk:V MXSyOFU3OTVzOR?=
L-540  NWXEXWV6TnWwY4Tpc44hSXO|YYm= M3nJWVYx6oDLzszt MW[x5qCKcA>? NYDmZpJjeHKndnXueJMhfGinIH3peI9kcG:wZILpZYwhdWWvYoLhcoUh\GWyb3zhdol7[XSrb36= MWGyOFU3OTVzOR?=
L-540  MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmnnOlDjiIoQvH2= Mkm2NgKBkWh? MnTadoVlfWOnczD0bIUhT2m4aX7vd5RifC:Vb4Lh[oVvcWJvaX7keYNm\CClZXzsJIRm[XSq NWH3S3JJOjR3NkG1NVk>
AGS NFfnSXVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlLvOlDjiIoQvH2= MkH2NgKBkWh? NH70c|hxemW4ZX70d{B{cGmtb37pck1qdmS3Y3XkJINmdGxiZHXheIg> NIDxNoozPDR4M{G5PS=>
NRK-52E  NFr3VJNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NIfNUFEzOCEQvF2= NVf4cmJXOjRiaB?= NU\zUo9[eHKxdHXjeJMh[2WubIOg[pJwdSClZXzsJIRm[XSqIHPheZNm\CCkeTDpd4Np\W2rYTDpcop2enl? MViyOFM2OTh2NR?=
NRK-52E  MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{mxXlIxKM7:TR?= MkDaNlQhcA>? NVnwdWRRcW6lcnXhd4V{KGOnbHygeoli[mmuaYT5JIFnfGW{IGTOSk3PuSCVdHnteYxifGmxbjDhcoQhSVSSIFTldIxmfGmxbh?= NXvIR|BTOjR|NUG4OFU>
NRK-52E  MnK5R4VtdCCYaXHibYxqfHliQYPzZZk> NVrBZ4NqOjBizszN NWnYUms4OjRiaB?= MljtbY5pcWKrdIOgbY5kemWjc3XkJGRzeDFicILveIVqdiCneIDy[ZN{cW:wIHHmeIVzKFSQRj5OtUBUfGmvdXzheIlwdiCjbnSgRXRRKESncHzleIlwdg>? NFnV[I4zPDN3MUi0OS=>
L929 NVS1R3hNTnWwY4Tpc44hSXO|YYm= MorHNk82yqEQvHevcYzDqA>? MmfxNlTDqGh? NHz5SpBz\X[ncoPl[EB1cGViYYX0c5Bp[We7IHnu[JVk\WRiYomgWG5H|rFiYXzvcoUh[XNid3XscEBieyCWTldOteKhM8Liem\BSC=> MlLSNlM6PDF5Nkm=
L929 NVfzU2FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLpR|VIOi93wrFOwIcwdW{EoB?= NI\RZXozPMLiaB?= MV3y[ZZmenOnczD0bIUh[2WubDDndo94fGhiaX7obYJqfGmxbjDhcoQh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IGTOSu6yKGGub37lJIF{KHenbHygZZMhXE6IzsJCpEvDqHqYQVS= NFXWRpIzOzl2MUe2PS=>
L929 MoDlSpVv[3Srb36gRZN{[Xl? NXG2dHl5OsLizsznM41tyqB? NEjDXJQzPMLiaB?= NUPhRZFReHKxbX;0d{Bk[XOyYYPlMVYhMHB{MDmgZYN1cX[rdImgZY5lKHC{b3Phd5Bie2VvNjDjcIVifmGpZR?= NUfvOIh4OjN7NEG3Olk>
L929 NGDTR|JHfW6ldHnvckBCe3OjeR?= NIrZOYw2yqEQvHevcYw> M{jpN|I1yqCq MVzicI9kc3Niem\BSEBqdmS3Y3XkJI5m[3KxcITvd4l{KGGwZDDheZRweGijZ4m= MXKyN|k1OTd4OR?=
C6 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHjFWWEyKG2vb3yvUC=> M1XUS|MhcA>? NUf6V4xV[XS2ZX71ZZRmeyCVaHnrc45qdiCrbnT1Z4VlKGeuaX;tZUBk\WyuIHTlZZRp NGfMUY0zOzh2MES0NS=>
U87 M3LNWWNmdGxiVnnhZoltcXS7IFHzd4F6 MVSxJI1ud2xxTB?= MmjYN{Bp MnjOZZR1\W63YYTld{BUcGmtb37pckBqdmS3Y3XkJIdtcW:vYTDj[YxtKGSnYYTo NYC0d5NWOjN6NEC0OFE>
C6 NFnxV3VEgXSxdH;4bYNqfHliQYPzZZk> M1nrSFEhdW2xbD;M MVizJIg> M3zpfoJtd2OtczDzbIlsd26rbjDpcoR2[2WmIH7lZ5Jwe2m| M2j3fVI{QDRyNESx
U87 MkXwR5l1d3SxeHnjbZR6KEG|c3H5 NF;6S3IyKG2vb3yvUC=> MoLwN{Bp NYH6[YtR[myxY3vzJJNpcWuxbnnuJIlv\HWlZXSgcoVkem:|aYO= MmO3NlM5PDB2NEG=
C6 MV\GeY5kfGmxbjDBd5NigQ>? MomzNUBudW:uL1y= MnvpNU42NTNiaB?= NF;w[oJ{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKFKLUD2xJINifXOnZDDifUB{cGmtb37pci=> NFPEe4ozOzh2MES0NS=>
U87 M1fuOWZ2dmO2aX;uJGF{e2G7 MV:xJI1ud2xxTB?= M2XwbVEvPS1|IHi= NV2wfoNke3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCUSWCtNUBk[XW|ZXSgZpkhe2ira3;ubY4> M2jRfVI{QDRyNESx
TE671 NHzERXJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUnwOo1xPDEkgJpOwIcwdW{EoB?= Ml7QNlQhcA>? NHT1OlJz\XOldXXzJGdZOTVvMEewMYlv\HWlZXSgcI9{eyCxZjDj[YxtKH[rYXLpcIl1gQ>? NUfTOWlOOjN5NESyPVY>
RMS13 NGfHNXdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MknVOFDjiIoQvHevcYzDqA>? MWOyOEBp M2Hs[ZJme2O3ZYOgS3gyPS1yN{CtbY5lfWOnZDDsc5N{KG:oIHPlcIwhfmmjYnnsbZR6 NH\RWoMzOzd2NEK5Oi=>
MEFs M2jQTWN6fG:2b4jpZ4l1gSCDc4PhfS=> NFexeVgzNzZxMkCg{txO M4PQblE5KGh? NHnvZ4xqdmirYnn0d{BVVkcQsT3pcoR2[2WmIHPlcIwh\GWjdHigbY4hWmWuQTDLU{BOTU[| NFrBZZMzOzd{N{W4NS=>
MEFs NGjwPWtHfW6ldHnvckBCe3OjeR?= NYPzNXFxOjEEoN88US=> NGf1bHQyNzJxNDDo MlTRd5VxeHKnc4Pld{BVVkcQsT3pcoR2[2WmIGLJVGsyKHCqb4PwbI9zgWyjdHnvci=> NFHZV3UzOzd{N{W4NS=>
ΔN-Karpas 299  NYLHfFllS3m2b4TvfIlkcXS7IFHzd4F6 NUS3N3lxOjEEoN88US=> NVnnUohjOTZiaB?= MULpcohq[mm2czDDSFMxNWmwZIXj[YQh[2WubDDk[YF1cA>? MmL0NlM2PDV7M{i=
MM.1S  MXXDfZRwfG:6aXPpeJkhSXO|YYm= NEfiT|M6OCEEtV2= NGTOW2EyKGh? MUDicI9kc3NiQlHZJFEyNTdyOEKgbY5lfWOnZDDyZZBq\CClZXzsJJN4\WyuaX7n M2LNb|I{PTJ5MUW0
KMS-12-BM NGHhPJNEgXSxdH;4bYNqfHliQYPzZZk> MnHyPVAhyrWP MlfyNUBp NVLrTI5b[myxY3vzJGJCYSBzMT23NFgzKGmwZIXj[YQhemGyaXSgZ4VtdCC|d3XscIlv\w>? NYrO[3FjOjN3MkexOVQ>
HT-22  MnXzR4VtdCCYaXHibYxqfHliQYPzZZk> NXfYVnJNOTEEoN88US=> MoHONVLDqGh? MV\EUXNQ M3Pq[JBzd3SnY4TzJIFo[Wmwc4Sg[4x2fGGvYYTlMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NWXYNHZ6OjN|MEe3OVI>
HT-22  MVnGeY5kfGmxbjDBd5NigQ>? NHyyNYYzPcLizszN NF;ob4Ux6oDVM{FCpI1qdg>? MmHUSG1UVw>? MnnYbY5pcWKrdIOgSXJMKEGldHn2ZZRqd25iaX7keYNm\CCkeTDncJV1[W2jdHW= NELHRpEzOzNyN{e1Ni=>
NIH3T3  MVTGeY5kfGmxbjDBd5NigQ>? MYOxNE82OCEQvF2= M{C0[lEwOyCq NXjYW4pN[W2nbHnvdoF1\XNiVF7G{tEu\HKrdnXuJINwdXCuZYig[o9zdWG2aX;u M4HBblI{OjZzNke3
SH-EP NHPHdGRCeG:ydH;zbZMhSXO|YYm= NYTWTHhYOTEkgJpOwG3DqA>? MmXSO|LjiImqwrC= NYnse5FIcW6qaXLpeJMhUUGSIHnubIljcXSxcj2gZY5lKEyneHH0eY12dWGkLXnu[JVk\WRiYYDvdJRwe2m| M33XXlIzQDlyM{Ky
HL60 MoHxRZBweHSxc3nzJGF{e2G7 MYK2NEDPxE1? NFLXSpUyOiCq MWflcohidmOnczDzbIlsd26rbj3pcoR2[2WmIHHwc5B1d3Orcx?= NHzSUY8zOjh|N{[4PS=>
HL60/Adr NWnpUoFwSXCxcITvd4l{KEG|c3H5 NXWzOFFoPjBizszN MWWxNkBp NEniflFmdmijbnPld{B{cGmtb37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MUSyNlg{PzZ6OR?=
K562 M3nIe2Fxd3C2b4Ppd{BCe3OjeR?= Mn\JOlAh|ryP M2facFEzKGh? NY\ofZND\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM> NEXUfpIzOjh|N{[4PS=>
K562/Adr  NWLnZXg{SXCxcITvd4l{KEG|c3H5 NELxZ4c3OCEQvF2= NXzSZ3NtOTJiaB?= M3LBOYVvcGGwY3XzJJNpcWuxbnnuMYlv\HWlZXSgZZBweHSxc3nz M4niVFIzQDN5Nki5
HL60 MkCwSpVv[3Srb36gRZN{[Xl? NUS2bI5zPjBizszN MUexNkBp M2nNS4F2\22nboTzJJRp\SClYYPwZZNmNTNiYXP0bZZqfHl? MWSyNlg{PzZ6OR?=
HL60/Adr NH\iRpVHfW6ldHnvckBCe3OjeR?= MUe2NEDPxE1? MVixNkBp NUXPWWo{[XWpbXXueJMhfGinIHPhd5Bie2VvMzDhZ5Rqfmm2eR?= MVqyNlg{PzZ6OR?=
K562 NIDtdXpHfW6ldHnvckBCe3OjeR?= MWC2NEDPxE1? Ml74NVIhcA>? MoT0ZZVodWWwdIOgeIhmKGOjc4Dhd4UuOyCjY4Tpeol1gQ>? NYrQSGJCOjJ6M{e2PFk>
K562/Adr  MoTQSpVv[3Srb36gRZN{[Xl? MXu2NEDPxE1? NEjUb5YyOiCq M1zOc4F2\22nboTzJJRp\SClYYPwZZNmNTNiYXP0bZZqfHl? MVqyNlg{PzZ6OR?=
HL60 M4DjVmZ2dmO2aX;uJGF{e2G7 MV:2NEDPxE1? MnfmNVIhcA>? MXTpcoNz\WG|ZYOgeIhmKGGldHn2bZR6KG:oIHPhd5Bie2W|LDDjZZNx[XOnIEigZY5lKDl? NYm3Wo9vOjJ6M{e2PFk>
HL60/Adr MoLpSpVv[3Srb36gRZN{[Xl? NEKzPG83OCEQvF2= Mni5NVIhcA>? NYPt[ZFtcW6lcnXhd4V{KHSqZTDhZ5Rqfmm2eTDv[kBk[XOyYYPld{wh[2G|cHHz[UA5KGGwZDC5 MXSyNlg{PzZ6OR?=
K562 NFSyWINHfW6ldHnvckBCe3OjeR?= MmD3OlAh|ryP MUSxNkBp NEGzOJhqdmO{ZXHz[ZMhfGinIHHjeIl3cXS7IH;mJINie3Cjc3XzMEBk[XOyYYPlJFgh[W6mIEm= MVqyNlg{PzZ6OR?=
K562/Adr  MUfGeY5kfGmxbjDBd5NigQ>? MUS2NEDPxE1? M{LWeFEzKGh? MUXpcoNz\WG|ZYOgeIhmKGGldHn2bZR6KG:oIHPhd5Bie2W|LDDjZZNx[XOnIEigZY5lKDl? MoDwNlI5Ozd4OEm=
L929sA NWfo[lE5SXCxcITvd4l{KEG|c3H5 NWXvZZg4OTBizszN NV[wUVVoOSCq NWnGU4F4cW6qaXLpeJMhfGinIHHwc5B1d3SrYzDy[ZNxd26|ZTD0c{BVVkZ? M3v3WlIzOzZ{N{[3
L929sA M1ztRWFxd3C2b4Ppd{BCe3OjeR?= MXyxNEDPxE1? NIHUVWgyKGh? NXjud5FSemW|Y4Xld{Bk\WyuczDlfJBz\XO|aX7nJHJKWEtzzqTJSEBnem:vIGTOSk1qdmS3Y3XkJIFxd3C2b4Ppdy=> NIC2Z|MzOjN4Mke2Oy=>
L929sA MUXBdI9xfG:|aYOgRZN{[Xl? MV2xNEDPxE1? NIXqfXgyKGh? NI\UV5li[nKxZ3H0[ZMhfGinIHnueIVz[WO2aX;uJI9nKGOjc4Dhd4UuQCC5aYToJGZCTER? NGX4TWczOjN4Mke2Oy=>
TPC-1 NGKxN2NE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3TrXlExOCEQvF2= NUHLe2tkOjRiaB?= MVjEUXNQ NH7RfYVqdmO{ZXHz[ZMh[2WubIXsZZIhe3W{dnn2ZYw> M1Tje|IzOTN4OEG4
8505c NXPPfJJ1S2WubDDWbYFjcWyrdImgRZN{[Xl? NH;BRYkyODBizszN MlnMNlQhcA>? MVjEUXNQ M{DBTYlv[3KnYYPld{Bk\WyudXzhdkB{fXK4aY\hcC=> M{H6UFIzOTN4OEG4
SW13 M2fPPWNmdGxiVnnhZoltcXS7IFHzd4F6 MnTFNVAxKM7:TR?= NXHwbplTOjRiaB?= NXzqdHVpTE2VTx?= M{DkN4lv[3KnYYPld{Bk\WyudXzhdkB{fXK4aY\hcC=> NVXE[JpwOjJzM{[4NVg>
Jurkat  M3m2UWN6fG:2b4jpZ4l1gSCDc4PhfS=> MYm1NE8hOTByL{KwNOKh|ryv NFrYU|cyNzNiaB?= MmTEdoVlfWOnc9MgUoFm\2yncnnhJIZwf2yncnmtbY5lfWOnZDDjfZRwfG:6aXPpeJk> MYmyNVU{PTB{MB?=
Jurkat  NWTnNoozTnWwY4Tpc44hSXO|YYm= NVvDOGlUOjBywrFOwI0> NVLiNI5yOzBibXnu NH63TVlz\WS3Y3XzxsBP[WWpbHXybYEh\m:5bHXybU1qdmS3Y3XkJJJm[WO2aY\lJI95gWenbjDzdIVkcWW|IDjSU3MqKGenbnXyZZRqd25? M2Px[VIyPTN3MEKw
HT-22 MXnDfZRwfG:6aXPpeJkhSXO|YYm= MmnaNVAh|ryP NUTHfVNzOTJiaB?= Mor1dJJwfGWldIOgZYdicW6|dDDj[YxtKGSnYYToJIlv\HWlZXSgZpkhPcLibX3vcE9NKGeudYThcYF1\cLi MnnmNVc4PjB6Nkm=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Immunofluorescence
RIP1 / RIP3 ; 

PubMed: 30462730     


Immunofluorscence data showed an increased expression of RIP1 and RIP3 in Pg-LPS group and an eminent reduction of RIP1 in the Pg-LPS+Nec-1 group.

30462730

Protocol

Kinase Assay:

[1]

- Collapse

RIP1 kinase assay:

Phosphorylation of RIP1 requires its kinase activity. Expression constructs of FLAGtagged wild-type (WT) or a kinase-inactive pointmutant of RIP1 (K45M) are are transfected into 293T cells and RIP1 kinase assay is performed as described in the Methods in the presence of [γ-32P]ATP for 30 min at 30℃. Samples are subjected to SDS-PAGE and RIP1 band is visualized by autoradiography. Relative intensities of radioactive bands are quantified and are shown (ratio) in this and all other autoradiographs. In parallel to kinase reactions, a sample of beads is subjected to western blot analysis using anti-RIP1 antibody to ensure equal protein amounts in kinase reactions.
Cell Research:

[2]

- Collapse
  • Cell lines: Jurkat, BALB/c 3T3, SV40-transformed MEF, L929
  • Concentrations: 0.01-100 μM
  • Incubation Time: --
  • Method:

    Cells are seeded in 96-well plates (white plates for luminescent assays; black plates for fluorescent assays; clear plates for MTT assay) at the density of 5,000-10,000 cells per well for adherent cells or 20,000-50,000 cells per well for suspension cells in 100 μl of the appropriate phenol red-free media. After incubation, we determined cell viability using one of the following methods. For the ATP assay, we used luminescence-based commercial kits and analyzed luminescence using a Wallac Victor II plate reader. For Sytox assay, we incubated cells with 1 μM Sytox Green reagent for 30 min at 37℃, and then performed fluorescent reading. Subsequently, we added 5 μl of 20% Triton X-100 solution into each well to produce maximal lysis and incubated cells for 1 h at 37℃, then performed the second reading. We calculated the ratio of values before and after Triton treatment and normalized it to the relevant controls not subjected to cytotoxic stimuli, as indicated in figure legends. For the MTT assay, we used the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit. For PI exclusion assays, we added 2 μg/ml PI into the medium and immediately analyzed samples using FACSCalibur. For PI-annexin V assay we used the ApoAlert Annexin V-EGFP Apoptosis Kit. For DioC6 staining, we incubated cells with 40 nM DiOC6 for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. For ROS analysis, we incubated cells with 5 μM dihydroethidium for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. EM analyses are performed at the Harvard Medical School EM facility. We acquired bright-field images of the cells using an Axiovert 200 microscope.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 51 mg/mL warmed (196.66 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 259.33
Formula

C13H13N3OS

CAS No. 4311-88-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

TNF-alpha Signaling Pathway Map

Related TNF-alpha Products

Tags: buy Necrostatin-1 | Necrostatin-1 supplier | purchase Necrostatin-1 | Necrostatin-1 cost | Necrostatin-1 manufacturer | order Necrostatin-1 | Necrostatin-1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID